

Generate Collection

Search Results - Record(s) 1 through 59 of 59 returned.

☐ 1. Document ID: US 6204053 B1

L9: Entry 1 of 59

File: USPT

Mar 20, 2001

US-PAT-NO: 6204053

DOCUMENT-IDENTIFIER: US 6204053 B1

TITLE: Porcine cortical cells and their use in treatment of neurological deficits due to neurodegenerative diseases

DATE-ISSUED: March 20, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dinsmore; Jonathan	Brookline	MA	N/A	N/A

US-CL-CURRENT: 435/325; 424/93.7, 435/374

ABSTRACT:

Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

16 Claims, 49 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 19

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 2. Document ID: US 6180343 B1

L9: Entry 2 of 59

File: USPT

Jan 30, 2001

US-PAT-NO: 6180343

DOCUMENT-IDENTIFIER: US 6180343 B1

TITLE: Green fluorescent protein fusions with random peptides

DATE-ISSUED: January 30, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Anderson; David	San Bruno	CA	N/A	N/A
Bogenberger; Jakob Maria	Menlo Park	CA	N/A	N/A

US-CL-CURRENT: 435/6; 435/320.1, 536/23.4

ABSTRACT:

The invention relates to the use of fluorescent proteins, particularly green fluorescent protein (GFP), in fusion constructs with random and defined peptides and peptide libraries, to increase the cellular expression levels, decrease the cellular catabolism, increase the conformational stability relative to linear peptides, and to increase the steady state concentrations of the random peptides and random peptide library members expressed in cells for the purpose of detecting the presence of the peptides and screening random peptide libraries. N-terminal, C-terminal, dual N- and C-terminal and one or more internal fusions are all contemplated. Novel fusions utilizing self-binding peptides to create a conformationally stabilized fusion domain are also contemplated.

21 Claims, 7 Drawing figures Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 3. Document ID: US 6177592 B1

L9: Entry 3 of 59

File: USPT

Jan 23, 2001

US-PAT-NO: 6177592
DOCUMENT-IDENTIFIER: US 6177592 B1

TITLE: Compounds

DATE-ISSUED: January 23, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Koyama; Nobuto	Otsu	N/A	N/A	JPX
Enoki; Tatsuji	Otsu	N/A	N/A	JPX
Ikai; Katsushige	Otsu	N/A	N/A	JPX
Wu; Hua-Kang	Otsu	N/A	N/A	JPX
Ohnogi; Hiromu	Otsu	N/A	N/A	JPX
Tominaga; Takanari	Otsu	N/A	N/A	JPX
Nishiyama; Eiji	Otsu	N/A	N/A	JPX
Hagiya; Michio	Otsu	N/A	N/A	JPX
Sagawa; Hiroaki	Otsu	N/A	N/A	JPX
Chono; Hideto	Otsu	N/A	N/A	JPX
Kato; Ikunoshin	Otsu	N/A	N/A	JPX

US-CL-CURRENT: 562/503

ABSTRACT:

A compound represented by the following formula [I] or an optically active substance or a salt thereof. ##STR1##

(In the formula, a bond shown by a dotted line in the five-membered ring means that said five-membered ring may be any of a cyclopentene ring having a double bond and a cyclopentane ring where said bond is saturated and, in the case of a cyclopentene ring, X is OH, Y is .dbd.O and Z is H while, in the case of a cyclopentane ring, X is .dbd.O, Y is OH and Z is OH. R is a residue after removal of an SH group from the SH-containing compound.)

22 Claims, 48 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 48

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 4. Document ID: US 6171856 B1

L9: Entry 4 of 59

File: USPT

Jan 9, 2001

US-PAT-NO: 6171856
DOCUMENT-IDENTIFIER: US 6171856 B1

TITLE: Methods and compositions relating to no-mediated cytotoxicity

DATE-ISSUED: January 9, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thigpen; Anice	Dallas	TX	N/A	N/A
Hohmeier; Hans-Ewald	Dallas	TX	N/A	N/A
Newgard; Christopher B.	Dallas	TX	N/A	N/A
Unger; Roger H.	Dallas	TX	N/A	N/A
Shimabukuro; Michio	Okinawa	N/A	N/A	JPX
Chen; Guoxun	Dallas	TX	N/A	N/A
Rhodes; Christopher J.	Dallas	TX	N/A	N/A
Hugl; Sigrun R.	Irving	TX	N/A	N/A
Cousin; Sharon	Irving	TX	N/A	N/A

US-CL-CURRENT: 435/325; 424/196.11, 424/204.1, 424/93.21, 424/93.3,
424/94.4, 435/14, 435/176, 435/183, 435/234, 435/235.1, 435/252.3,
435/254.11, 435/3, 435/30, 435/317.1, 435/320.1, 435/34, 435/366,
435/372.3, 435/375, 435/440, 435/455, 435/465, 435/69.1, 435/69.4,
435/69.7, 514/10, 514/14, 514/169, 514/31, 514/564, 514/806, 514/9

ABSTRACT:

The present invention relates to methods and compositions for the treatment of diabetes involving free radicals. In particular, the present invention is directed to the treatment or prophylactic intervention of diabetes. The present invention demonstrates that MnSOD can play a protective role against cytokine killing, and provides strategies for engineering cell lines as islet surrogates for transplantation therapy of diabetes mellitus. Further, the present invention shows that .beta.-cell destruction and dysfunction in adipogenic diabetes is mediated via fatty acids. Methods and compositions for ameliorating this disorder are provided herein.

4 Claims, 28 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 22

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 5. Document ID: US 6165476 A

L9: Entry 5 of 59

File: USPT

Dec 26, 2000

US-PAT-NO: 6165476

DOCUMENT-IDENTIFIER: US 6165476 A

TITLE: Fusion proteins with an immunoglobulin hinge region linker

DATE-ISSUED: December 26, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Strom; Terry B.	Brookline	MA	N/A	N/A
Zhen; Xin Xiao	Brookline	MA	N/A	N/A

US-CL-CURRENT: 424/195.11; 424/85.2, 435/252.3, 435/320.1, 435/325,
435/69.7, 530/351, 530/387.3, 530/399, 536/23.4

ABSTRACT:

The present invention relates to the production and use of fusion proteins with an immunoglobulin hinge region linker.

20 Claims, 0 Drawing figures Exemplary Claim Number: 1,10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWOC	Drawl Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------	-------

☐ 6. Document ID: US 6159731 A

L9: Entry 6 of 59

File: USPT

Dec 12, 2000

US-PAT-NO: 6159731
DOCUMENT-IDENTIFIER: US 6159731 A

TITLE: Daxx, a Fas-binding protein that activates JNK and apoptosis

DATE-ISSUED: December 12, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yang; Xiaolu	Philadelphia	PA	N/A	N/A
Khosravi-Far; Roya	Malden	MA	N/A	N/A
Chang; Howard Y.	Cambridge	MA	N/A	N/A
Baltimore; David	Pasadena	CA	N/A	N/A

US-CL-CURRENT: 435/325; 435/320.1, 435/357, 435/367, 435/369,
435/440, 435/69.1, 530/350, 536/23.1, 536/23.5, 536/24.31 , 536/24.33

ABSTRACT:

The invention describes nucleic acids encoding the Daxx protein, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such nucleic acids, and antibodies relating thereto. Methods and products for using such nucleic acids and polypeptides also are provided.

14 Claims, 10 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 7. Document ID: US 6159464 A

L9: Entry 7 of 59

File: USPT

Dec 12, 2000

US-PAT-NO: 6159464
DOCUMENT-IDENTIFIER: US 6159464 A

TITLE: Viral vectors to inhibit leukocyte infiltration or cartilage degradation of joints

DATE-ISSUED: December 12, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Glorioso; Joseph C.	Cheswick	PA	N/A	N/A
Evans; Christopher H.	Pittsburgh	PA	N/A	N/A
Robbins; Paul D.	Pittsburgh	PA	N/A	N/A
Ghivizzani; Steven C.	Allison Park	PA	N/A	N/A

US-CL-CURRENT: 424/93.2; 424/93.6, 514/825

ABSTRACT:

Methods for treating a connective tissue disorder by introducing at least one gene encoding a product into at least one target cell of a mammalian host for use in treating the mammalian host are disclosed. These methods include employing recombinant techniques to produce a vector molecule containing the DNA sequence encoding for the product and infecting the target cell of the mammalian host using the vector. The injection can be done in vivo, by directly injecting the vector into the host, or can be done in vitro by transfecting a population of cultured target cells with the vector and transplanting them each into the host. Nonviral means can also be used to introduce the DNA sequence to the host. Administration of more than one gene of interest results in an enhanced therapeutic benefit. Also disclosed is a method for treating a connective tissue disorder by introducing at least one gene encoding a product into at least one target cell of a joint of a host for use in treating multiple joints of the host. Injection of a vector molecule containing the DNA sequence encoding for a product of interest, or non-viral introduction of such a DNA sequence, to one joint of a mammalian host results in a therapeutic benefit in that joint as well as other joints in the host

7 Claims, 62 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 40

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 8. Document ID: US 6156878 A

L9: Entry 8 of 59

File: USPT

Dec 5, 2000

US-PAT-NO: 6156878
DOCUMENT-IDENTIFIER: US 6156878 A

TITLE: Ligand (ACT-4-L) to a receptor on the surface of activated CD4.sup.+ T-cells

DATE-ISSUED: December 5, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Godfrey; Wayne	White Bear Lake	MN	N/A	N/A
Engleman; Edgar G.	Atherton	CA	N/A	N/A
Buck; David	Santa Clara	CA	N/A	N/A

US-CL-CURRENT: 530/350; 530/300

ABSTRACT:

The invention provides ligands and fragments thereof to a receptor on the surface of activated CD4.sup.+ T-cells. An exemplary ligand is designated ACT-4-L-h-1. Preferred fragments include purified extracellular domains of ligands. The invention also provides humanized and human antibodies to the ligand. The invention further provides methods of using the ligand and the antibodies in treatment of diseases and conditions of the immune system. The invention also provides methods of monitoring activated CD4.sup.+ T-cells using the ligands or fragments thereof.

6 Claims, 10 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 9. Document ID: US 6156304 A

L9: Entry 9 of 59

File: USPT

Dec 5, 2000

US-PAT-NO: 6156304
DOCUMENT-IDENTIFIER: US 6156304 A

TITLE: Gene transfer for studying and treating a connective tissue of a mammalian host

DATE-ISSUED: December 5, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Glorioso; Joseph C.	Cheswick	PA	N/A	N/A
Evans; Christopher H.	Pittsburgh	PA	N/A	N/A
Robbins; Paul D.	Pittsburgh	PA	N/A	N/A

US-CL-CURRENT: 424/93.2

ABSTRACT:

Methods for introducing at least one gene encoding a product into at least one target cell of a mammalian host for use in treating the mammalian host are disclosed. These methods include employing recombinant techniques to produce a vector molecule that contains the gene encoding for the product, and infecting the target cells of the mammalian host using the DNA vector molecule. A method to produce an animal model for the study of connective tissue pathology is also disclosed.

12 Claims, 56 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 26

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWOC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 10. Document ID: US 6153402 A

L9: Entry 10 of 59

File: USPT

Nov 28, 2000

US-PAT-NO: 6153402
DOCUMENT-IDENTIFIER: US 6153402 A

TITLE: Death domain containing receptors

DATE-ISSUED: November 28, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Darnestown	MD	N/A	N/A
Ni; Jian	Rockville	MD	N/A	N/A
Gentz; Reiner L.	Silver Spring	MD	N/A	N/A
Dillon; Patrick J.	Gaithersburg	MD	N/A	N/A

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 536/23.5

ABSTRACT:

The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.

61 Claims, 6 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 11. Document ID: US 6153380 A

L9: Entry 11 of 59

File: USPT

Nov 28, 2000

US-PAT-NO: 6153380
DOCUMENT-IDENTIFIER: US 6153380 A

TITLE: Methods for screening for transdominant intracellular effector peptides and RNA molecules

DATE-ISSUED: November 28, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Nolan; Garry P.	Palo Alto	CA	N/A	N/A
Rothenberg; S. Michael	Palo Alto	CA	N/A	N/A

US-CL-CURRENT: 435/6; 435/325, 435/69.1, 435/70.1, 435/91.1,
536/23.1, 536/24.3, 536/24.31, 536/24.5

ABSTRACT:

Methods and compositions for screening for intracellular transdominant effector peptides and RNA molecules selected inside living cells from randomized pools are provided.

27 Claims, 4 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 12. Document ID: US 6143867 A

L9: Entry 12 of 59

File: USPT

Nov 7, 2000

US-PAT-NO: 6143867
DOCUMENT-IDENTIFIER: US 6143867 A

TITLE: Human eosinophil-derived basic protein

DATE-ISSUED: November 7, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Akerblom; Ingrid E.	Redwood City	CA	N/A	N/A

US-CL-CURRENT: 530/350; 530/380, 530/829, 530/851

ABSTRACT:

The present invention provides a human eosinophil-derived basic protein (EBPH) and polynucleotides which identify and encode EBPH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding EBPH and a method for producing EBPH. The invention also provides for use of EBPH and agonists, antibodies or antagonists specifically binding EBPH, in the prevention and treatment of diseases associated with expression of EBPH. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding EBPH for the treatment of diseases associated with the expression of EBPH. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding EBPH.

6 Claims, 4 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMAC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 13. Document ID: US 6114307 A

L9: Entry 13 of 59

File: USPT

Sep 5, 2000

US-PAT-NO: 6114307
DOCUMENT-IDENTIFIER: US 6114307 A

TITLE: Methods for stimulating pancreatic islet cell regeneration

DATE-ISSUED: September 5, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jaspers; Stephen R.	Edmonds	WA	N/A	N/A
Sprugel; Katherine H.	Seattle	WA	N/A	N/A
Ren; Hong Ping	Kirkland	WA	N/A	N/A
Humes; Jacqueline M.	Seattle	WA	N/A	N/A
Conklin; Darrell C.	Seattle	WA	N/A	N/A

US-CL-CURRENT: 514/12; 514/2, 514/3, 514/866, 530/399

ABSTRACT:

The present invention provides compositions for stimulating an increase in islet proliferation and .beta.-cell mass using an insulin homolog polypeptide. The present invention also includes methods for treating diabetes by stimulating islet proliferation and .beta.-cell mass increases and affecting insulin levels.

8 Claims, 2 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 14. Document ID: US 6110507 A

L9: Entry 14 of 59

File: USPT

Aug 29, 2000

US-PAT-NO: 6110507
DOCUMENT-IDENTIFIER: US 6110507 A

TITLE: Human 3-hydroxyisobutryl-coenzyme a hydrolase

DATE-ISSUED: August 29, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bandman; Olga	Mountain View	CA	N/A	N/A
Guegler; Karl J.	Menlo Park	CA	N/A	N/A
Corley; Neil C.	Mountain View	CA	N/A	N/A
Shah; Purvi	Sunnyvale	CA	N/A	N/A

US-CL-CURRENT: 424/94.6; 424/139.1, 435/196, 435/7.1, 530/387.9

ABSTRACT:

The present invention provides a human 3-hydroxyisobutyryl-coenzyme A hydrolase (HIBCOH) and polynucleotides which identify and encode HIBCOH. The invention also provides expression vectors, host cells, and antibodies. The invention also provides methods for the prevention and treatment of diseases associated with expression of HIBCOH, as well as diagnostic assays.

9 Claims, 8 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 15. Document ID: US 6103497 A

L9: Entry 15 of 59

File: USPT

Aug 15, 2000

US-PAT-NO: 6103497
DOCUMENT-IDENTIFIER: US 6103497 A

TITLE: Human S100 proteins

DATE-ISSUED: August 15, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hillman; Jennifer L.	Mountain View	CA	N/A	N/A
Bandman; Olga	Mountain View	CA	N/A	N/A
Corley; Neil C.	Mountain View	CA	N/A	N/A
Lal; Preeti	Sunnyvale	CA	N/A	N/A
Shah; Purvi	Sunnyvale	CA	N/A	N/A

US-CL-CURRENT: 435/69.1; 530/300, 536/23.5, 536/24.3

ABSTRACT:

The invention provides two human S100 proteins designated individually as S100P1 and S100P2 and collectively as S100P, and polynucleotides which identify and encode S100P. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of S100P.

6 Claims, 13 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KUMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 16. Document ID: US 6093565 A

L9: Entry 16 of 59

File: USPT

Jul 25, 2000

US-PAT-NO: 6093565
DOCUMENT-IDENTIFIER: US 6093565 A

TITLE: Protein phosphatase regulatory subunit

DATE-ISSUED: July 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hillman; Jennifer L.	San Jose	CA	N/A	N/A
Goli; Surya K.	Sunnyvale	CA	N/A	N/A

US-CL-CURRENT: 435/252.3; 435/196, 435/320.1, 435/325, 435/440,
435/6, 435/69.1, 435/69.2, 536/23.1, 536/23.2, 536/23.5

ABSTRACT:

The present invention provides a human protein phosphatase regulatory subunit (HCNB) and polynucleotides which identify and encode HCNB. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HCNB and a method for producing HCNB. The invention also provides for agonists, antibodies, or antagonists specifically binding HCNB, and their use, in the prevention and treatment of diseases associated with expression of HCNB. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HCNB for the treatment of diseases associated with the expression of HCNB. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HCNB.

5 Claims, 7 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 17. Document ID: US 6071874 A

L9: Entry 17 of 59

File: USPT

Jun 6, 2000

US-PAT-NO: 6071874
DOCUMENT-IDENTIFIER: US 6071874 A

TITLE: Human pathogenesis-related protein

DATE-ISSUED: June 6, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bandman; Olga	Mountain View	CA	N/A	N/A
Goli; Surya K.	Sunnyvale	CA	N/A	N/A

US-CL-CURRENT: 514/2; 435/252.33, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The present invention provides a human pathogenesis-related protein (HPRP) and polynucleotides which identify and encode HPRP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPRP and a method for producing HPRP. The invention also provides for agonists, antibodies, or antagonists specifically binding HPRP, and their use, in the prevention and treatment of diseases associated with expression of HPRP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPRP for the treatment of diseases associated with the expression of HPRP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPRP.

2 Claims, 8 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 18. Document ID: US 6060054 A

L9: Entry 18 of 59

File: USPT

May 9, 2000

US-PAT-NO: 6060054
DOCUMENT-IDENTIFIER: US 6060054 A

TITLE: Product for T lymphocyte immunosuppression

DATE-ISSUED: May 9, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Staerz; Uwe D.	Denver	CO	N/A	N/A

US-CL-CURRENT: 424/134.1; 424/192.1, 424/193.1, 435/455, 435/471,
435/69.1, 514/8, 514/885, 530/350, 530/387.3, 530/391.1

ABSTRACT:

The present invention relates to a product and process for suppressing an immune response using a T lymphocyte immunosuppression molecule capable of blocking cell surface molecules responsible for T cell activation. Disclosed is a CD4 or CD2 molecule, associated with an immunoglobulin molecule capable of binding to a major histocompatibility antigen. Also disclosed is a method to produce a T lymphocyte molecule, a therapeutic composition comprising a T lymphocyte immunosuppression molecule and methods to use T lymphocyte immunosuppression molecules in therapeutic processes requiring suppression of an immune response.

31 Claims, 5 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KUMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 19. Document ID: US 6060317 A

L9: Entry 19 of 59

File: USPT

May 9, 2000

US-PAT-NO: 6060317
DOCUMENT-IDENTIFIER: US 6060317 A

TITLE: Method of transducing mammalian cells, and products related thereto

DATE-ISSUED: May 9, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Malech; Harry L.	Bethesda	MD	N/A	N/A

US-CL-CURRENT: 435/456; 435/304.1, 435/320.1, 435/325, 530/350

ABSTRACT:

In accordance with the present invention, there are provided methods of transducing cells comprising providing a flexible closed culture container having cells therein and contacting said cells with a viral-vector in the presence of a multi-functional chemical moiety. Also provided are methods of delivering a functional protein to a subject in need thereof, comprising transducing mammalian cells according to the invention method and introducing said cells into a subject in need thereof. Also provided are cell-culture systems for transducing cells, comprising a flexible closed culture container and a multi-functional chemical moiety therein.

20 Claims, 6 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 20. Document ID: US 6054292 A

L9: Entry 20 of 59

File: USPT

Apr 25, 2000

US-PAT-NO: 6054292
DOCUMENT-IDENTIFIER: US 6054292 A

TITLE: T-cell receptor protein

DATE-ISSUED: April 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hillman; Jennifer L.	Mountain View	CA	N/A	N/A
Corley; Neil C.	Mountain View	CA	N/A	N/A

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/455, 530/350,
536/23.5

ABSTRACT:

The invention provides a human T-cell receptor protein (TCRLP) and polynucleotides which identify and encode TCRLP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of TCRLP.

7 Claims, 6 Drawing figures Exemplary Claim Number: 1,5,6,7
Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 21. Document ID: US 6030945 A

L9: Entry 21 of 59

File: USPT

Feb 29, 2000

US-PAT-NO: 6030945
DOCUMENT-IDENTIFIER: US 6030945 A

TITLE: Apo-2 ligand

DATE-ISSUED: February 29, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ashkenazi; Avi J.	San Mateo	CA	N/A	N/A

US-CL-CURRENT: 514/12; 424/192.1, 424/198.1, 530/350, 930/140,
930/144

ABSTRACT:

A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.

22 Claims, 14 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 22. Document ID: US 6017527 A

L9: Entry 22 of 59

File: USPT

Jan 25, 2000

US-PAT-NO: 6017527
DOCUMENT-IDENTIFIER: US 6017527 A

TITLE: Activated dendritic cells and methods for their activation

DATE-ISSUED: January 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Maraskovsky; Eugene	Seattle	WA	N/A	N/A
Mc Kenna; Hilary J.	Seattle	WA	N/A	N/A

US-CL-CURRENT: 424/93.71; 424/93.7, 435/2, 435/325, 435/375, 435/377,
435/455

ABSTRACT:

Antigen-expressing, activated dendritic cells are disclosed. Such dendritic cells are used to present tumor, viral or bacterial antigens to T cells, and can be useful in vaccination protocols. Other cytokines can be used in separate, sequential or simultaneous combination with the activated, antigen-pulsed dendritic cells. Also disclosed are methods for stimulating an immune response using the antigen-expressing, activated dendritic cells.

15 Claims, 3 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMOC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 23. Document ID: US 6017729 A

L9: Entry 23 of 59

File: USPT

Jan 25, 2000

US-PAT-NO: 6017729
DOCUMENT-IDENTIFIER: US 6017729 A

TITLE: Receptor activator of NF-.kappa.B

DATE-ISSUED: January 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Anderson; Dirk M.	Seattle	WA	N/A	N/A
Galibert; Laurent	Seattle	WA	N/A	N/A
Maraskovsky; Eugene	Caulfield Nth	N/A	N/A	AUX

US-CL-CURRENT: 435/69.1; 435/235.1, 435/252.3, 435/320.1, 435/325,
435/70.1, 530/350, 536/23.1, 536/24.31

ABSTRACT:

Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.

14 Claims, 3 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------	-------

☐ 24. Document ID: US 6015884 A

L9: Entry 24 of 59

File: USPT

Jan 18, 2000

US-PAT-NO: 6015884
DOCUMENT-IDENTIFIER: US 6015884 A

TITLE: Soluble divalent and multivalent heterodimeric analogs of proteins

DATE-ISSUED: January 18, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schneck; Jonathan	Silver Spring	MD	N/A	N/A
O'Herrin; Sean	Baltimore	MD	N/A	N/A

US-CL-CURRENT: 530/387.3; 530/388.1

ABSTRACT:

Specificity in immune responses is in part controlled by the selective interaction of T cell receptors with their cognate ligands, peptide/MHC molecules. The discriminating nature of this interaction makes these molecules, in soluble form, good candidates for selectively regulating immune responses. Attempts to exploit soluble analogs of these proteins has been hampered by the intrinsic low avidity of these molecules for their ligands. To increase the avidity of soluble analogs for their cognates to biologically relevant levels, divalent peptide/MHC complexes or T cell receptors (superdimers) were constructed. Using a recombinant DNA strategy, DNA encoding either the MHC class II/peptide or TCR heterodimers was ligated to DNA coding for murine Ig heavy and light chains. These constructs were subsequently expressed in a baculovirus expression system. Enzyme-linked immunosorbant assays (ELISA) specific for the Ig and polymorphic determinants of either the TCR or MHC fraction of the molecule indicated that infected insect cells secreted approximately 1 .mu.g/ml of soluble, conformationally intact chimeric superdimers. SDS PAGE gel analysis of purified protein showed that expected molecular weight species. The results of flow cytometry demonstrated that the TCR and class II chimeras bound specifically with high avidity to cells bearing their cognate receptors. These superdimers will be useful for studying TCR/MHC interactions, lymphocyte tracking, identifying new antigens, and have possible uses as specific regulators of immune responses.

10 Claims, 18 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 16

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 25. Document ID: US 6010853 A

L9: Entry 25 of 59

File: USPT

Jan 4, 2000

US-PAT-NO: 6010853
DOCUMENT-IDENTIFIER: US 6010853 A

TITLE: Siva genes, novel genes involved in CD27-mediated apoptosis

DATE-ISSUED: January 4, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kanteti; Prasad V. S.	Boston	MA	N/A	N/A
Ao; Zhaohui	Devon	PA	N/A	N/A
Schlossman; Stuart F.	Newton Centre	MA	N/A	N/A

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/91.4,
435/91.5, 536/23.1, 536/23.4, 536/23.5

ABSTRACT:

The invention provides isolated nucleic acids molecules, designated Siva nucleic acid molecules, which encode proteins involved in immune cell apoptosis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing Siva nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a Siva gene has been introduced or disrupted. The invention still further provides isolated Siva proteins, fusion proteins, antigenic peptides and anti-Siva antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

16 Claims, 2 Drawing figures Exemplary Claim Number: 1,8
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 26. Document ID: US 5958725 A

L9: Entry 26 of 59

File: USPT

Sep 28, 1999

US-PAT-NO: 5958725
DOCUMENT-IDENTIFIER: US 5958725 A

TITLE: Human DP1 homolog

DATE-ISSUED: September 28, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bandman; Olga	Mountain View	CA	N/A	N/A
Guegler; Karl J.	Menlo Park	CA	N/A	N/A
Shah; Purvi	Sunnyvale	CA	N/A	N/A
Petithory; Joanne R.	Union City	CA	N/A	N/A
Corley; Neil C.	Mountain View	CA	N/A	N/A

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

The invention provides a human DP1 homolog (DPlh)) and polynucleotides which identify and encode DPlh. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of DPlh.

8 Claims, 6 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 27. Document ID: US 5955429 A

L9: Entry 27 of 59

File: USPT

Sep 21, 1999

US-PAT-NO: 5955429
DOCUMENT-IDENTIFIER: US 5955429 A

TITLE: Human apoptosis-associated protein

DATE-ISSUED: September 21, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hillman; Jennifer L.	San Jose	CA	N/A	N/A
Goli; Surya K.	Sunnyvale	CA	N/A	N/A

US-CL-CURRENT: 514/12; 530/350

ABSTRACT:

The present invention provides a novel human apoptosis-associated protein (NHAAP) and polynucleotides which identify and encode NHAAP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NHAAP and a method for producing NHAAP. The invention also provides for agonists, antibodies, or antagonists specifically binding NHAAP, and their use, in the prevention and treatment of diseases associated with expression of NHAAP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NHAAP for the treatment of diseases associated with the expression of NHAAP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NHAAP.

3 Claims, 3 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 28. Document ID: US 5948626 A

L9: Entry 28 of 59

File: USPT

Sep 7, 1999

US-PAT-NO: 5948626
DOCUMENT-IDENTIFIER: US 5948626 A

TITLE: Method of detecting human phospholipase inhibitor

DATE-ISSUED: September 7, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hawkins; Phillip R.	Mountain View	CA	N/A	N/A
Murry; Lynn E.	Portola Valley	CA	N/A	N/A

US-CL-CURRENT: 435/6

ABSTRACT:

The present invention provides a polynucleotide (gipl) the partial sequence for which was initially isolated from a THP-1 cDNA library and which identifies and encodes a novel human phospholipase inhibitor (GIPL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding GIPL. The invention also provides for the use of purified GIPL and its agonists in pharmaceutical compositions for the treatment of diseases associated with the abnormal or excess phospholipase activity. Additionally, the invention provides for the use of antisense molecules to gipl or inhibitors of GIPL in pharmaceutical compositions for the prevention of pregnancy or treatment of Alzheimer's disease. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of gipl, or anti-GIPL antibodies which specifically bind to the polypeptide, GIPL.

1 Claims, 22 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 22

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 29. Document ID: US 5935931 A

L9: Entry 29 of 59

File: USPT

Aug 10, 1999

US-PAT-NO: 5935931
DOCUMENT-IDENTIFIER: US 5935931 A

TITLE: Human apoptosis-related calcium-binding protein

DATE-ISSUED: August 10, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hillman; Jennifer L.	San Jose	CA	N/A	N/A
Goli; Surya K.	Sunnyvale	CA	N/A	N/A

US-CL-CURRENT: 514/12; 530/300, 530/350

ABSTRACT:

The present invention provides a human apoptosis-related calcium-binding protein (HARC) and polynucleotides which identify and encode HARC. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HARC and a method for producing HARC. The invention also provides for agonists, antibodies, or antagonists specifically binding HARC, and their use, in the prevention and treatment of diseases associated with expression of HARC. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HARC for the treatment of diseases associated with the expression of HARC. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HARC.

2 Claims, 5 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 30. Document ID: US 5925734 A

L9: Entry 30 of 59

File: USPT

Jul 20, 1999

US-PAT-NO: 5925734
DOCUMENT-IDENTIFIER: US 5925734 A

TITLE: Isolated Epstein-Barr virus BZLF2 proteins that bind MHC class II .beta.chains

DATE-ISSUED: July 20, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP	CODE	COUNTRY
Alderson; Mark	Bainbridge Island	WA	N/A		N/A
Armitage; Richard J.	Bainbridge Island	WA	N/A		N/A
Cohen; Jeffrey I.	Silver Spring	MD	N/A		N/A
Comeau; Michael R.	Seattle	WA	N/A		N/A
Farrah; Theresa M.	Seattle	WA	N/A		N/A
Hutt-Fletcher; Lindsey M.	Kansas City	MO	N/A		N/A
Spriggs; Melanie K.	Seattle	WA	N/A		N/A

US-CL-CURRENT: 530/350; 435/69.3, 530/387.3

ABSTRACT:

Isolated viral proteins, and pharmaceutical compositions made therefrom, are disclosed which are capable of binding to a .beta. chain of a Class II Major Histocompatibility Complex antigen, thereby functioning to inhibit an antigen-specific response. The viral proteins also have superantigen-like activity, and inhibit EBV infection.

6 Claims, 11 Drawing figures Exemplary Claim Number: 1,3
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMHC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 31. Document ID: US 5925521 A

L9: Entry 31 of 59

File: USPT

Jul 20, 1999

US-PAT-NO: 5925521

DOCUMENT-IDENTIFIER: US 5925521 A

TITLE: Human serine carboxypeptidase

DATE-ISSUED: July 20, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bandman; Olga	Mountain View	CA	N/A	N/A
Hawkins; Phillip R.	Mountain View	CA	N/A	N/A
Hillman; Jennifer L.	Mountain View	CA	N/A	N/A
Lal; Preeti	Sunnyvale	CA	N/A	N/A
Goli; Surya K.	Sunnyvale	CA	N/A	N/A

US-CL-CURRENT: 435/6; 435/226, 435/252.3, 435/320.1, 435/325,
536/23.2, 536/24.31

ABSTRACT:

The present invention provides a human serine carboxypeptidase (CPEPT) and polynucleotides which identify and encode CPEPT. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of CPEPT.

9 Claims, 9 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 32. Document ID: US 5922565 A

L9: Entry 32 of 59

File: USPT

Jul 13, 1999

US-PAT-NO: 5922565

DOCUMENT-IDENTIFIER: US 5922565 A

TITLE: Human clathrin-associated protein

DATE-ISSUED: July 13, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hillman; Jennifer L.	Mountain View	CA	N/A	N/A
Goli; Surya K.	Sunnyvale	CA	N/A	N/A

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/7.1, 530/350,
536/23.1, 536/23.5

ABSTRACT:

The present invention provides a human clathrin-associated protein (HAP19) and polynucleotides which identify and encode HAP19. The invention also provides expression vectors and host cells and a method for producing HAP19. The invention also provides antibodies or antagonists specifically binding HAP19, and their use, in the prevention and treatment of diseases associated with expression of HAP19. The invention also provides diagnostic assays.

5 Claims, 2 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 33. Document ID: US 5919629 A

L9: Entry 33 of 59

File: USPT

Jul 6, 1999

US-PAT-NO: 5919629
DOCUMENT-IDENTIFIER: US 5919629 A

TITLE: Polynucleotide probe and detection method for novel human clathrin-associated protein

DATE-ISSUED: July 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hillman; Jennifer L.	Mountain View	CA	N/A	N/A
Goli; Surya K.	Sunnyvale	CA	N/A	N/A

US-CL-CURRENT: 435/6; 536/23.5, 536/24.31

ABSTRACT:

The present invention provides a human clathrin-associated protein (HAP19) and polynucleotides which identify and encode HAP19. The invention also provides expression vectors and host cells and a method for producing HAP19. The invention also provides antibodies or antagonists specifically binding HAP19, and their use, in the prevention and treatment of diseases associated with expression of HAP19. The invention also provides diagnostic assays.

2 Claims, 2 Drawing figures Exemplary Claim Number: 2
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 34. Document ID: US 5916749 A

L9: Entry 34 of 59

File: USPT

Jun 29, 1999

US-PAT-NO: 5916749
DOCUMENT-IDENTIFIER: US 5916749 A

TITLE: Human phosphatase inhibitor protein

DATE-ISSUED: June 29, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bandman; Olga	Mountain View	CA	N/A	N/A
Goli; Surya K.	Sunnyvale	CA	N/A	N/A

US-CL-CURRENT: 435/6; 435/252.3, 435/320.1, 435/325, 435/69.2,
536/23.1, 536/23.5

ABSTRACT:

The present invention provides a novel human phosphatase inhibitor protein (HPIP) and polynucleotides which identify and encode HPIP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPIP and a method for producing HPIP. The invention also provides for agonists, antibodies, or antagonists specifically binding HPIP, and their use, in the prevention and treatment of diseases associated with expression of HPIP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPIP for the treatment of diseases associated with the expression of HPIP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPIP.

10 Claims, 7 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 35. Document ID: US 5892016 A

L9: Entry 35 of 59

File: USPT

Apr 6, 1999

US-PAT-NO: 5892016
DOCUMENT-IDENTIFIER: US 5892016 A

TITLE: Human tumor suppressor

DATE-ISSUED: April 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Brie; Sam La	Mountain View	CA	N/A	N/A
Goli; Surya K.	Sunnyvale	CA	N/A	N/A

US-CL-CURRENT: 536/23.5; 435/7.23, 530/324, 530/350

ABSTRACT:

The present invention provides a novel human tumor suppressor (NHTS) and polynucleotides which identify and encode NHTS. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NHTS and a method for producing NHTS. The invention also provides for agonists, antibodies, or antagonists specifically binding NHTS, and their use, in the prevention and treatment of diseases associated with expression of NHTS. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NHTS for the a treatment of diseases associated with the expression of NHTS. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NHTS.

6 Claims, 5 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 36. Document ID: US 5879893 A

L9: Entry 36 of 59

File: USPT

Mar 9, 1999

US-PAT-NO: 5879893
DOCUMENT-IDENTIFIER: US 5879893 A

TITLE: Method of screening for human protein kinase C inhibitor homolog

DATE-ISSUED: March 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Au-Young; Janice	Berkeley	CA	N/A	N/A
Hawkins; Phillip R.	Mountain View	CA	N/A	N/A
Hillman; Jennifer L.	San Jose	CA	N/A	N/A

US-CL-CURRENT: 435/6; 536/23.1, 536/23.5, 536/24.3, 536/24.31

ABSTRACT:

The present invention provides a polynucleotide (ipkc) which identifies and encodes a novel human protein kinase C inhibitor homolog (IPKC). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding IPKC. The invention also provides for the use of purified IPKC and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of IPKC. Additionally, the invention provides for the use of antisense molecules to ipkc in pharmaceutical compositions for treatment of diseases associated with the expression of IPKC. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of ipkc. The present invention also relates to anti-IPKC antibodies which specifically bind to IPKC.

2 Claims, 6 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------	-------

☐ 37. Document ID: US 5861495 A

L9: Entry 37 of 59

File: USPT

Jan 19, 1999

US-PAT-NO: 5861495
DOCUMENT-IDENTIFIER: US 5861495 A

TITLE: Human zinc binding proteins

DATE-ISSUED: January 19, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hillman; Jennifer L.	Palo Alto	CA	N/A	N/A
Au-Young; Janice	Palo Alto	CA	N/A	N/A
Coleman; Roger	Palo Alto	CA	N/A	N/A
Goli; Surya K.	Palo Alto	CA	N/A	N/A

US-CL-CURRENT: 536/23.1; 435/252.3, 435/273, 435/320.1, 435/69.1,
435/69.3, 435/71.1, 530/350, 536/23.5

ABSTRACT:

The present invention provides three zinc binding proteins (designated individually as ZB-1, ZB-2, and ZB-3, and collectively as ZB) and polynucleotides which identify and encode ZB. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding ZB and a method for producing ZB. The invention also provides for use of ZB and agonists, antibodies, or antagonists specifically binding ZB, in the prevention and treatment of diseases associated with expression of ZB. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding ZB for the treatment of diseases associated with the expression of ZB. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding ZB.

8 Claims, 25 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 22

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 38. Document ID: US 5858712 A

L9: Entry 38 of 59

File: USPT

Jan 12, 1999

US-PAT-NO: 5858712
DOCUMENT-IDENTIFIER: US 5858712 A

TITLE: CDNA encoding a LEA-motif developmental protein homologous to avian px19

DATE-ISSUED: January 12, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hillman; Jennifer L.	Mountain View	CA	N/A	N/A
Goli; Surya K.	Sunnyvale	CA	N/A	N/A

US-CL-CURRENT: 435/69.1; 435/252.3, 435/254.11, 435/320.1, 435/325,
536/23.5, 536/24.31

ABSTRACT:

px19 is an avian gene recently identified as a bromodeoxyuridine (BrdU)-sensitive transcript associated with hematopoiesis in early chick development. Its translation product contains an "LEA" (late embryogenesis abundant) motif which had previously been observed only in plant seed proteins. The present invention provides nucleic acids encoding a human LEA motif protein (HuLEAP) homologous to the avian px19 gene product. Also provided are expression vectors, transformed host cells, and methods of using them to produce recombinant HuLEAP polypeptides.

8 Claims, 5 Drawing figures Exemplary Claim Number: 1,2
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw. Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------	-------

☐ 39. Document ID: US 5855880 A

L9: Entry 39 of 59

File: USPT

Jan 5, 1999

US-PAT-NO: 5855880
DOCUMENT-IDENTIFIER: US 5855880 A

TITLE: Avirulent microbes and uses therefor

DATE-ISSUED: January 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Curtiss, III; Roy	St. Louis	MO	N/A	N/A
Kelly; Sandra M.	St. Louis	MO	N/A	N/A

US-CL-CURRENT: 424/93.2; 424/184.1, 424/200.1, 424/235.1, 424/257.1,
424/258.1, 424/93.48, 435/252.3, 435/252.33, 435/320.1, 435/879

ABSTRACT:

This invention provides immunogenic compositions for the immunization of a vertebrate or invertebrate comprising an avirulent derivative of *S. typhi*. The derivatives having a mutation of the *cya* and/or *crp* and/or *cdt* genes. The invention also provides immunogenic compositions for the immunization of a vertebrate and invertebrate comprising an avirulent derivative of the above type which is capable of expressing a recombinant gene derived from a pathogen of said vertebrate or invertebrate individual to produce an antigen capable of inducing an immune response against said pathogen. Other embodiments of the invention include methods of preparing immunogenic compositions from these strains, and strains useful in the preparation of the immunogenic compositions, as well as methods of stimulating the immune system to respond to an immunogenic antigen of *S. typhi* by administration of the immunogenic composition.

9 Claims, 6 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw. Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	------------	-------

☐ 40. Document ID: US 5855879 A

L9: Entry 40 of 59

File: USPT

Jan 5, 1999

US-PAT-NO: 5855879

DOCUMENT-IDENTIFIER: US 5855879 A

TITLE: Avirulent microbes and uses therefor

DATE-ISSUED: January 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Curtiss III; Roy	St. Louis	MO	N/A	N/A

US-CL-CURRENT: 424/93.2; 424/184.1, 424/200.1, 424/235.1, 424/257.1,
424/258.1, 424/93.48, 435/252.3, 435/252.33, 435/320.1, 435/879

ABSTRACT:

This invention provides immunogenic compositions for the immunization of a vertebrate or invertebrate comprising an avirulent derivative of *S. typhi*. The derivatives having a mutation of the *cya* and/or *crp* and/or *cdt* genes. The invention also provides immunogenic compositions for the immunization of a vertebrate and invertebrate comprising an avirulent derivative of the above type which is capable of expressing a recombinant gene derived from a pathogen of said vertebrate or invertebrate individual to produce an antigen capable of inducing an immune response against said pathogen. Other embodiments of the invention include methods of preparing immunogenic compositions from these strains, and strains useful in the preparation of the immunogenic compositions, as well as methods of stimulating the immune system to respond to an immunogenic antigen of *S. typhi* by administration of the immunogenic composition.

9 Claims, 6 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 41. Document ID: US 5856130 A

L9: Entry 41 of 59

File: USPT

Jan 5, 1999

US-PAT-NO: 5856130
DOCUMENT-IDENTIFIER: US 5856130 A

TITLE: Human pathogenesis-related protein

DATE-ISSUED: January 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bandman; Olga	Mountain View	CA	N/A	N/A
Goli; Surya K.	Sunnyvale	CA	N/A	N/A

US-CL-CURRENT: 435/69.1; 435/252.3, 435/252.33, 435/320.1, 530/350,
536/23.1, 536/23.5, 536/24.31

ABSTRACT:

The present invention provides a human pathogenesis-related protein (HPRP) and polynucleotides which identify and encode HPRP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPRP and a method for producing HPRP. The invention also provides for agonists, antibodies, or antagonists specifically binding HPRP, and their use, in the prevention and treatment of diseases associated with expression of HPRP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPRP for the treatment of diseases associated with the expression of HPRP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPRP.

7 Claims, 8 Drawing figures Exemplary Claim Number: 2
Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw. Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------	-------

☐ 42. Document ID: US 5856129 A

L9: Entry 42 of 59

File: USPT

Jan 5, 1999

US-PAT-NO: 5856129
DOCUMENT-IDENTIFIER: US 5856129 A

TITLE: DNA encoding a human purinoceptor

DATE-ISSUED: January 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hillman; Jennifer L.	San Jose	CA	N/A	N/A
Coleman; Roger	Mountain View	CA	N/A	N/A

US-CL-CURRENT: 435/69.1; 435/252.3, 435/254.11, 435/320.1, 435/325,
536/23.5, 536/24.31

ABSTRACT:

The present invention provides a novel human P.sub.2X purinoreceptor (HPURR) and polynucleotides which identify and encode HPURR. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPURR and a method for producing HPURR. The invention also provides for use of HPURR, and agonists, antibodies or antagonists specifically binding HPURR, in the prevention and treatment of diseases associated with expression of HPURR. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPURR for the treatment of diseases associated with the expression of HPURR. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPURR.

8 Claims, 11 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 43. Document ID: US 5849498 A

L9: Entry 43 of 59

File: USPT

Dec 15, 1998

US-PAT-NO: 5849498
DOCUMENT-IDENTIFIER: US 5849498 A

TITLE: Human 3-hydroxyisobutyryl-coenzyme a hydrolase

DATE-ISSUED: December 15, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bandman; Olga	Mountain View	CA	N/A	N/A
Guegler; Karl J.	Menlo Park	CA	N/A	N/A
Corley; Neil C.	Mountain View	CA	N/A	N/A
Shah; Purvi	Sunnyvale	CA	N/A	N/A

US-CL-CURRENT: 435/6; 435/196, 435/252.3, 435/320.1, 536/23.2

ABSTRACT:

The present invention provides a human 3-hydroxyisobutyryl-coenzyme A hydrolase (HIBCOH) and polynucleotides which identify and encode HIBCOH. The invention also provides expression vectors, host cells, and antibodies. The invention also provides methods for the prevention and treatment of diseases associated with expression of HIBCOH, as well as diagnostic assays.

10 Claims, 8 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw. Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------	-------

☐ 44. Document ID: US 5837493 A

L9: Entry 44 of 59

File: USPT

Nov 17, 1998

US-PAT-NO: 5837493
DOCUMENT-IDENTIFIER: US 5837493 A

TITLE: Human galectins

DATE-ISSUED: November 17, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hillman; Jennifer L.	San Jose	CA	N/A	N/A
Goli; Surya K.	Sunnyvale	CA	N/A	N/A
Bandman; Olga	Mountain View	CA	N/A	N/A
Hawkins; Phillip R.	Mountain View	CA	N/A	N/A
Petithory; Joanne R.	Fremont	CA	N/A	N/A

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/325, 435/348,
435/371, 536/23.1, 536/23.5

ABSTRACT:

The present invention provides two novel human galectins (designated individually as GAL-5HA and GAL-5HB, and collectively as GAL-5H) and polynucleotides which identify and encode GAL-5H. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding GAL-5H and a method for producing GAL-5H. The invention also provides for use of GAL-5H and agonists, antibodies, or antagonists specifically binding GAL-5H, in the prevention and treatment of diseases associated with expression of GAL-5H. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding GAL-5H for the treatment of diseases associated with the expression of GAL-5H. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding GAL-5H.

9 Claims, 9 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 45. Document ID: US 5821332 A

L9: Entry 45 of 59

File: USPT

Oct 13, 1998

US-PAT-NO: 5821332
DOCUMENT-IDENTIFIER: US 5821332 A

TITLE: Receptor on the surface of activated CD4.sup.+ T-cells: ACT-4

DATE-ISSUED: October 13, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Godfrey; Wayne	Woodside	CA	N/A	N/A
Buck; David	Half Moon Bay	CA	N/A	N/A
Engleman; Edgar G.	Atherton	CA	N/A	N/A

US-CL-CURRENT: 530/350; 530/300, 530/324, 530/325, 530/326, 530/327,
530/328, 530/329, 530/330

ABSTRACT:

The invention provides purified ACT-4 receptor polypeptides, antibodies against these polypeptides and nucleic acids encoding ACT-4 receptor polypeptides. Also provided are methods of diagnosis and treatment using the same. ACT-4 receptors are preferentially expressed on the surface of activated CD4.sup.+ T-cells. ACT-4 receptors are usually expressed at low levels on the surface of activated CD8.sup.+ cells, and are usually substantially absent on resting T-cells, and on monocytes and B-cells (resting or activated). An exemplary ACT-4 receptor, termed ACT-4-h-1, has a signal sequence, an extracellular domain comprising three disulfide-bonded intrachain loops, a transmembrane domain, and an intracellular domain.

7 Claims, 18 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMMC	Draw. Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------	-------

☐ 46. Document ID: US 5817480 A

L9: Entry 46 of 59

File: USPT

Oct 6, 1998

US-PAT-NO: 5817480
DOCUMENT-IDENTIFIER: US 5817480 A

TITLE: DNA encoding a histamine H2 receptor

DATE-ISSUED: October 6, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Murry; Lynn E.	Portola Valley	CA	N/A	N/A
Au-Young; Janice	Berkeley	CA	N/A	N/A
Guegler; Karl J.	Menlo Park	CA	N/A	N/A
Goli; Surya K.	Sunnyvale	CA	N/A	N/A

US-CL-CURRENT: 435/69.1; 435/91.41, 530/350, 536/23.5

ABSTRACT:

The present invention provides a novel histamine H2 receptor (H2RH) and polynucleotides which identify and encode H2RH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding H2RH and a method for producing H2RH. The invention also provides for agonists, antibodies, or antagonists specifically binding H2RH, and their use, in the prevention and treatment of diseases in which H2RH is expressed. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding H2RH for the treatment of diseases associated with the expression of H2RH. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding H2RH.

7 Claims, 14 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 14

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 47. Document ID: US 5811520 A

L9: Entry 47 of 59

File: USPT

Sep 22, 1998

US-PAT-NO: 5811520

DOCUMENT-IDENTIFIER: US 5811520 A

TITLE: Human phospholipase inhibitor protein

DATE-ISSUED: September 22, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hawkins; Phillip R.	Mountain View	CA	N/A	N/A
Murry; Lynn E.	Portola Valley	CA	N/A	N/A

US-CL-CURRENT: 530/350

ABSTRACT:

The present invention provides a polynucleotide (gipl) the partial sequence for which was initially isolated from a THP-1 cDNA library and which identifies and encodes a novel human phospholipase inhibitor (GIPL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding GIPL. The invention also provides for the use of purified GIPL and its agonists in pharmaceutical compositions for the treatment of diseases associated with the abnormal or excess phospholipase activity. Additionally, the invention provides for the use of antisense molecules to gipl or inhibitors of GIPL in pharmaceutical compositions for the prevention of pregnancy or treatment of Alzheimer's disease. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of gipl, or anti-GIPL antibodies which specifically bind to the polypeptide, GIPL.

2 Claims, 22 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 22

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw. Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------	-------

☐ 48. Document ID: US 5773580 A

L9: Entry 48 of 59

File: USPT

Jun 30, 1998

US-PAT-NO: 5773580
DOCUMENT-IDENTIFIER: US 5773580 A

TITLE: Human protein kinase c inhibitor homolog

DATE-ISSUED: June 30, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Au-Young; Janice	Berkley	CA	N/A	N/A
Hawkins; Phillip R.	Mountain View	CA	N/A	N/A
Hillman; Jennifer L.	San Jose	CA	N/A	N/A

US-CL-CURRENT: 530/350

ABSTRACT:

The present invention provides a polynucleotide (ipkc) which identifies and encodes a novel human protein kinase C inhibitor homolog (IPKC). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding IPKC. The invention also provides for the use of purified IPKC and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of IPKC. Additionally, the invention provides for the use of antisense molecules to ipkc in pharmaceutical compositions for treatment of diseases associated with the expression of IPKC. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of ipkc. The present invention also relates to anti-IPKC antibodies which specifically bind to IPKC.

2 Claims, 7 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 49. Document ID: US 5763220 A

L9: Entry 49 of 59

File: USPT

Jun 9, 1998

US-PAT-NO: 5763220
DOCUMENT-IDENTIFIER: US 5763220 A

TITLE: Human apoptosis-related calcium-binding protein

DATE-ISSUED: June 9, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hillman; Jennifer L.	San Jose	CA	N/A	N/A
Goli; Surya K.	Sunnyvale	CA	N/A	N/A

US-CL-CURRENT: 435/69.1; 435/252.3, 435/254.11, 435/320.1, 435/325,
536/23.5

ABSTRACT:

The present invention provides a human apoptosis-related calcium-binding protein (HARC) and polynucleotides which identify and encode HARC. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HARC and a method for producing HARC. The invention also provides for agonists, antibodies, or antagonists specifically binding HARC, and their use, in the prevention and treatment of diseases associated with expression of HARC. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HARC for the treatment of diseases associated with the expression of HARC. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HARC.

7 Claims, 7 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw. Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	------------	-------

☐ 50. Document ID: US 5759546 A

L9: Entry 50 of 59

File: USPT

Jun 2, 1998

US-PAT-NO: 5759546
DOCUMENT-IDENTIFIER: US 5759546 A

TITLE: Treatment of CD4 T-cell mediated conditions

DATE-ISSUED: June 2, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Weinberg; Andrew D.	Portland	OR	97201	N/A
Vandenbark; Arthur A.	Portland	OR	97221	N/A

US-CL-CURRENT: 424/179.1; 424/184.1, 424/185.1, 530/387.1, 530/387.3,
530/388.75, 530/866, 530/867, 530/868

ABSTRACT:

A method for the selective depletion of activated CD4.sup.+ T-cells in vivo by using immunotoxins comprising the OX-40 antibody conjugated to a toxic molecule (such as Ricin-A chain). The administration of these specific immunotoxins is used therapeutically to deplete autoimmune reactive CD4.sup.+ T-cells which have been implicated in diseases including Multiple Sclerosis, Rheumatoid Arthritis, Sarcoidosis, and Autoimmune Uveitis. This type of therapy is also beneficial for eradicating CD4.sup.+ T-cell lymphomas and alloreactive CD4.sup.+ T-cells involved with a transplantation reaction. The use of the human form of the OX-40 antibody will also help in the early diagnosis of all the diseases mentioned above.

23 Claims, 16 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------	-------

☐ 51. Document ID: US 5756332 A

L9: Entry 51 of 59

File: USPT

May 26, 1998

US-PAT-NO: 5756332
DOCUMENT-IDENTIFIER: US 5756332 A

TITLE: Guanosine monophosphate reductase

DATE-ISSUED: May 26, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hillman; Jennifer L.	San Jose	CA	N/A	N/A

US-CL-CURRENT: 435/189; 435/191, 435/252.3, 435/252.33, 435/320.1,
536/23.1, 536/23.2, 536/23.5

ABSTRACT:

The present invention provides a human guanosine monophosphate reductase (HGMPR) and polynucleotides which identify and encode HGMPR. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HGMPR and a method for producing HGMPR. The invention also provides for agonists, antibodies, or antagonists specifically binding HGMPR, and their use, in the prevention and treatment of diseases associated with expression of HGMPR. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HGMPR for the treatment of diseases associated with the expression of HGMPR. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HGMPR.

9 Claims, 11 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 52. Document ID: US 5738852 A

L9: Entry 52 of 59

File: USPT

Apr 14, 1998

US-PAT-NO: 5738852
DOCUMENT-IDENTIFIER: US 5738852 A

TITLE: Methods of enhancing antigen-specific T cell responses

DATE-ISSUED: April 14, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Robinson; William S.	Palo Alto	CA	N/A	N/A
Chu; Keting	Palo Alto	CA	N/A	N/A

US-CL-CURRENT: 424/199.1; 424/278.1, 424/93.2, 435/320.1, 514/44

ABSTRACT:

Recombinant polynucleotides are provided that confer at least partial immunity on an individual to an infectious intracellular pathogenic agent. The recombinant polynucleotides encode a costimulatory factor and/or a target antigen polypeptide. The immune response that confers the immunity results from the expression of both polypeptides in an antigen presenting cell in the individual. The immunity is to the pathogenic agent that naturally encodes the target antigen polypeptide.

15 Claims, 1 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw. Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------	-------

☐ 53. Document ID: US 5728820 A

L9: Entry 53 of 59

File: USPT

Mar 17, 1998

US-PAT-NO: 5728820
DOCUMENT-IDENTIFIER: US 5728820 A

TITLE: Human eosinophil-derived basic protein

DATE-ISSUED: March 17, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Akerblom; Ingrid E.	Redwood City	CA	N/A	N/A

US-CL-CURRENT: 536/23.5; 435/320.1, 435/325, 435/70.1, 536/24.31

ABSTRACT:

The present invention provides a human eosinophil-derived basic protein (EBPH) and polynucleotides which identify and encode EBPH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding EBPH and a method for producing EBPH. The invention also provides for use of EBPH and agonists, antibodies or antagonists specifically binding EBPH, in the prevention and treatment of diseases associated with expression of EBPH. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding EBPH for the treatment of diseases associated with the expression of EBPH. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding EBPH.

8 Claims, 3 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 54. Document ID: US 5726286 A

L9: Entry 54 of 59

File: USPT

Mar 10, 1998

US-PAT-NO: 5726286
DOCUMENT-IDENTIFIER: US 5726286 A

TITLE: Isolated epstein-barr virus BZLF2 proteins that bind MHC class II beta chains

DATE-ISSUED: March 10, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP	CODE	COUNTRY
Alderson; Mark	Bainbridge Island	WA	N/A		N/A
Armitage; Richard J.	Bainbridge Island	WA	N/A		N/A
Cohen; Jeffrey I.	Silver Spring	MD	N/A		N/A
Comeau; Michael R.	Seattle	WA	N/A		N/A
Farrah; Theresa M.	Seattle	WA	N/A		N/A
Hutt-Fletcher; Lindsey M.	Kansas City	MO	N/A		N/A
Spriggs; Melanie K.	Seattle	WA	N/A		N/A

US-CL-CURRENT: 530/300; 435/69.3, 530/350

ABSTRACT:

Isolated viral proteins, and pharmaceutical compositions made therefrom, are disclosed which are capable of binding to a .beta. chain of a Class II Major Histocompatibility Complex antigen, thereby functioning to inhibit an antigen-specific response. The viral proteins also have superantigen-like activity, and inhibit EBV infection.

2 Claims, 11 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------	-------

☐ 55. Document ID: US 5663059 A

L9: Entry 55 of 59

File: USPT

Sep 2, 1997

US-PAT-NO: 5663059

DOCUMENT-IDENTIFIER: US 5663059 A

TITLE: Human phospholipase inhibitor

DATE-ISSUED: September 2, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hawkins; Phillip R.	Mountain View	CA	N/A	N/A
Murry; Lynn E.	Portola Valley	CA	N/A	N/A

US-CL-CURRENT: 435/69.2; 435/320.1, 435/325, 435/348, 435/419,
536/23.5

ABSTRACT:

The present invention provides a polynucleotide (gipl) the partial sequence for which was initially isolated from a THP-1 cDNA library and which identifies and encodes a novel human phospholipase inhibitor (GIPL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding GIPL.

5 Claims, 21 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 21

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw. Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------	-------

☐ 56. Document ID: US 5648238 A

L9: Entry 56 of 59

File: USPT

Jul 15, 1997

US-PAT-NO: 5648238
DOCUMENT-IDENTIFIER: US 5648238 A

TITLE: Human protein kinase C inhibitor homolog

DATE-ISSUED: July 15, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Au-Young; Janice	Berkeley	CA	N/A	N/A
Hawkins; Phillip R.	Mountain View	CA	N/A	N/A
Hillman; Jennifer L.	San Jose	CA	N/A	N/A

US-CL-CURRENT: 435/69.2; 435/252.3, 435/254.2, 435/320.1, 435/325,
435/348, 435/419, 536/23.5

ABSTRACT:

The present invention provides a polynucleotide (ipkc) which identifies and encodes a novel human protein kinase C inhibitor homolog (IPKC). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding IPKC.

5 Claims, 6 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KM/C	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 57. Document ID: US 5552529 A

L9: Entry 57 of 59

File: USPT

Sep 3, 1996

US-PAT-NO: 5552529
DOCUMENT-IDENTIFIER: US 5552529 A

TITLE: Autoantigen, pinch

DATE-ISSUED: September 3, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rearden; Ann	Rancho Santa Fe	CA	N/A	N/A

US-CL-CURRENT: 530/380; 424/185.1, 530/327, 530/806, 530/829

ABSTRACT:

A novel autoantigenic polypeptide, PINCH, polynucleotides and antibodies that bind to PINCH are provided. A method for removing autoantibodies that bind to an epitope contained in PINCH from a sample, such as blood, and a method of treating autoimmune disorders associated with autoantibodies that bind an epitope in PINCH are also provided.

2 Claims, 6 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 58. Document ID: US 5387744 A

L9: Entry 58 of 59

File: USPT

Feb 7, 1995

US-PAT-NO: 5387744
DOCUMENT-IDENTIFIER: US 5387744 A

TITLE: Avirulent microbes and uses therefor: Salmonella typhi

DATE-ISSUED: February 7, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Curtiss, III; Roy	St. Louis	MO	N/A	N/A
Kelly; Sandra M.	St. Louis	MO	N/A	N/A

US-CL-CURRENT: 424/258.1; 435/252.3, 435/252.33, 435/320.1, 435/879

ABSTRACT:

This invention provides immunogenic compositions for the immunization of a vertebrate or invertebrate comprising an avirulent derivative of S. typhi. The derivatives having a mutation of the cya and/or crp and/or cdt genes. The invention also provides immunogenic compositions for the immunization of a vertebrate and invertebrate comprising an avirulent derivative of the above type which is capable of expressing a recombinant gene derived from a pathogen of said vertebrate or invertebrate individual to produce an antigen capable of inducing an immune response against said pathogen. Other embodiments of the invention include methods of preparing immunogenic compositions from these strains, and strains useful in the preparation of the immunogenic compositions, as well as methods of stimulating the immune system to respond to an immunogenic antigen of S. typhi by administration of the immunogenic composition.

11 Claims, 4 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 59. Document ID: US 5294441 A

L9: Entry 59 of 59

File: USPT

Mar 15, 1994

US-PAT-NO: 5294441
DOCUMENT-IDENTIFIER: US 5294441 A

TITLE: Avirulent microbes and uses therefor: salmonella typhi

DATE-ISSUED: March 15, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Curtiss, III; Roy	St. Louis	MO	N/A	N/A

US-CL-CURRENT: 424/200.1; 424/235.1, 424/258.1, 435/252.3,
435/252.33, 435/320.1, 435/879

ABSTRACT:

This invention provides immunogenic compositions for the immunization of a vertebrate or invertebrate comprising an avirulent derivative of *S. typhi*. The derivatives having a mutation of the *cya* and/or *crp* and/or *cdt* genes. The invention also provides immunogenic compositions for the immunization of a vertebrate and invertebrate comprising an avirulent derivative of the above type which is capable of expressing a recombinant gene derived from a pathogen of said vertebrate or invertebrate individual to produce an antigen capable of inducing an immune response against said pathogen. Other embodiments of the invention include methods of preparing immunogenic compositions from these strains, and strains useful in the preparation of the immunogenic compositions, as well as methods of stimulating the immune system to respond to an immunogenic antigen of *S. typhi* by administration of the immunogenic composition.

12 Claims, 6 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

Generate Collection

Term	Documents
(5 AND 6 AND 7 AND 8).USPT,PGPB,JPAB,EPAB,DWPI	59

Display

☐

Documents, starting with Document:

Display Format:

Change Format

[Generate Collection](#)**Search Results - Record(s) 1 through 14 of 14 returned.**☐ 1. Document ID: US 5985876 A

L2: Entry 1 of 14

File: USPT

Nov 16, 1999

US-PAT-NO: 5985876

DOCUMENT-IDENTIFIER: US 5985876 A

TITLE: Nucleophile substituted ecteinascidins and N-oxide
ecteinascidins

DATE-ISSUED: November 16, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rinehart; Kenneth L.	Urbana	IL	61801	N/A
Zhou; Tong	Urbana	IL	61801	N/A

US-CL-CURRENT: 514/250; 544/233, 544/340

ABSTRACT:

Five new nucleophile substituted ecteinascidin (Et) compounds have been isolated from extracts of Ecteinascidia turbinata. These compounds have been purified by chromatographic techniques and their structures and bioactivities have been determined. The five nucleophile substituted Et compounds have been designated herein as Et 802 (1), Et 788 (2), Et 760 (3), Et 858 (4) and Et 815 (5). Also obtained were three new N-oxide ecteinascidin compounds, which have been designated herein as Et 717 (6), Et 775 (7) and Et 789 (8). Some of these newly discovered Et compounds show exceedingly potent cytotoxicity against L1210.

27 Claims, 11 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 2. Document ID: US 5981829 A

L2: Entry 2 of 14

File: USPT

Nov 9, 1999

US-PAT-NO: 5981829

DOCUMENT-IDENTIFIER: US 5981829 A

TITLE: .DELTA.Nur77 transgenic mouse

DATE-ISSUED: November 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mountz; John D.	Birmingham	AL	N/A	N/A
Zhou; Tong	Birmingham	AL	N/A	N/A
Cheng; Jianhua	Alabaster	AL	N/A	N/A

US-CL-CURRENT: 800/18; 435/455, 536/23.1, 800/11, 800/21, 800/22,
800/25, 800/3

ABSTRACT:

The present invention provides a transgenic mouse containing a transgene, said transgene comprising a truncated Nur77 (.DELTA.Nur77) gene. Also provided is a double transgenic mouse, wherein said double transgenic mouse comprises the .DELTA.Nur77 transgenic mouse backcrossed with the D.sup.b /HY T cell receptor transgenic mouse.

12 Claims, 8 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 15

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMHC	Draw. Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------	-------

☐ 3. Document ID: US 5888764 A

L2: Entry 3 of 14

File: USPT

Mar 30, 1999

US-PAT-NO: 5888764
DOCUMENT-IDENTIFIER: US 5888764 A

TITLE: Human fas gene promoter region

DATE-ISSUED: March 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mountz; John D.	Birmingham	AL	N/A	N/A
Liu; Changdan	Alabaster	AL	N/A	N/A
Cheng; Jianhua	Alabaster	AL	N/A	N/A
Koopman; William J.	Indian Springs	AL	N/A	N/A
Zhou; Tong	W. Stonebrook Pl.	AL	N/A	N/A

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/325, 435/455,
435/458, 435/471, 435/472, 435/476, 536/23.5, 536/23.51 , 536/24.1,
536/24.31

ABSTRACT:

Disclosed is a 5' flanking sequence of the human fas gene containing a promoter region. This sequence also contains at least three transcription initiation sites, as well as consensus sequences for AP-1, GF-1, NY-Y, CP-2, EB20, and c-myb. Also disclosed are methods of altering senescence of the immune system by modifying Fas activity in cells to increase or decrease apoptosis. Fas expression and function on T cells from old (22-26-month-old) mice is also compared to young (2-month-old) mice and old CD2-fas transgenic mice. Fas expression and ligand-induced apoptosis was decreased on T cells from old mice compared to young mice. In 26-month-old CD2-fas transgenic mice, Fas and CD44 expression, Fas-induced apoptosis, T cell proliferation and cytokine production were comparable to that of the young mice. These results suggest that T cell senescence with age is associated with defective apoptosis and that the CD2-fas transgene allows the maintenance of Fas apoptosis function and T cell function in aged mice comparable to that of young mice.

46 Claims, 27 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 19

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 4. Document ID: WO 9622370 A1

L2: Entry 4 of 14

File: EPAB

Jul 25, 1996

PUB-NO: WO009622370A1
DOCUMENT-IDENTIFIER: WO 9622370 A1
TITLE: HUMAN FAS GENE PROMOTER REGION

PUBN-DATE: July 25, 1996

INVENTOR-INFORMATION:

NAME	COUNTRY
MOUNTZ, JOHN D	N/A
LIU, CHANGDAN	N/A
CHENG, JIANHUA	N/A
KOOPMAN, WILLIAM J	N/A
ZHOU, TONG	N/A

INT-CL (IPC): C12N 15/12; C07K 14/715; C12N 15/67; C12Q 1/68; A01K 67/027; C12N 1/21; C12N 5/10; C12N 15/86
EUR-CL (EPC): A01K067/027; C07K014/715, C12N015/67 , C12Q001/68

ABSTRACT:

Disclosed is a 5' flanking sequence of the human fas gene containing a promoter region. This sequence also contains at least three transcription initiation sites, as well as consensus sequences for AP-1, GF-1, NY-Y, CP-2, EB20, and c-myb. Also disclosed are methods of altering senescence of the immune system by modifying Fas activity in cells to increase or decrease apoptosis. Fas expression and function on T cells from old (22-26-month-old) mice is also compared to young (2-month-old) mice and old CD2-fas transgenic mice. Fas expression and ligand-induced apoptosis was decreased on T cells from old mice compared to young mice. In 26-month-old CD2-fas transgenic mice, Fas and CD44 expression, Fas-induced apoptosis, T cell proliferation and cytokine production were comparable to that of the young mice. These results suggest that T cell senescence with age is associated with defective apoptosis and that the CD2-fas transgene allows the maintenance of Fas apoptosis function and T cell function in aged mice comparable to that of young mice.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 5. Document ID: WO 9620206 A1

L2: Entry 5 of 14

File: EPAB

Jul 4, 1996

PUB-NO: WO009620206A1
DOCUMENT-IDENTIFIER: WO 9620206 A1
TITLE: SECRETED HUMAN FAS ANTIGEN

PUBN-DATE: July 4, 1996

INVENTOR-INFORMATION:

NAME	COUNTRY
MOUNTZ, JOHN D	N/A
LIU, CHANGDAN	N/A
ZHOU, TONG	N/A
CHENG, JIANHUA	N/A

INT-CL (IPC): C07H 21/04; C12Q 1/68; G01N 33/53; C07K 14/475; C07K 14/52; A61K 38/18; A61K 38/19
EUR-CL (EPC): C07K014/715; C12N015/62, G01N033/68

ABSTRACT:

Disclosed is a natural, soluble form of the Fas antigen polypeptide that is secreted by human cells and is the result of alternative mRNA processing in the cell. This variant of Fas is shown to be present at higher levels in patients with SLE and AILD. Also disclosed are nucleic acids encoding this unique form of the Fas antigen and methods for making and using the protein and nucleic acids, including various diagnostic embodiments such as ELISAs.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 6. Document ID: WO 9408454 A1

L2: Entry 6 of 14

File: EPAB

Apr 28, 1994

PUB-NO: WO009408454A1
DOCUMENT-IDENTIFIER: WO 9408454 A1
TITLE: METHODS, COMPOSITIONS AND SCREENING ASSAYS RELATING TO
AUTOIMMUNE DISEASE

PUBN-DATE: April 28, 1994

INVENTOR-INFORMATION:

NAME	COUNTRY
MOUNTZ, JOHN D	N/A
WU, JIANGUO	N/A

INT-CL (IPC): A01N 1/00; C07H 5/00; C07K 7/00; C07K 13/00; C12Q 1/00
EUR-CL (EPC): C07K014/715

ABSTRACT:

Disclosed herein is the discovery that the insertion of a retroviral transposon of the ETn family into the fas apoptosis gene coding region underlies the lpr/lpr rodent model of systemic autoimmune disease. These results establish a link between endogenous retrovirus expression and autoimmune disease. The present invention embodies both novel nucleic acid probes and new screening assays for use in the identification of agents for the treatment of autoimmune and lymphoproliferative diseases. The invention also contemplates new therapeutic strategies for autoimmune disease involving modulating the expression of retroviruses associated with tolerance-related or lymphocyte activation genes.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 7. Document ID: AU 9956896 A, WO 200011149 A1

L2: Entry 7 of 14

File: DWPI

Mar 14, 2000

DERWENT-ACC-NO: 2000-246560
DERWENT-WEEK: 200031
COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Producing high titers of recombinant adenoassociated virus comprising a therapeutic gene comprises infecting it and helper adenovirus comprising E1-deleted adeno virus genome into cells

INVENTOR: MOUNTZ, J D; ZHANG, H

PRIORITY-DATA: 1998US-0097666 (August 24, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 9956896 A	March 14, 2000	N/A	000	C12N015/00
WO 200011149 A1	March 2, 2000	E	083	C12N015/00

INT-CL (IPC): A01N 43/04; A01N 63/00; C07H 19/00; C12N 5/00; C12N 5/02; C12N 15/00

ABSTRACTED-PUB-NO: WO 200011149A

BASIC-ABSTRACT:

NOVELTY - Producing (I) high titers of recombinant adenoassociated virus (rAAV) comprising therapeutic gene (Th) comprises infecting cells with rAAV with adenoviral inverted repeats flanking the therapeutic gene and recombinant helper adeno virus (rhAV) comprising an E1-deleted adeno virus genome and AAV rep and cap genes.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method of producing high titers of rAAV-Th comprising infecting cells with a conditional packageable adenoviral helper vector, comprising genes encoding adenoviral packaging functions flanked by Loxp sequences, and at least one rAAV-Th, and purifying and titering the rAAV-Th; and

(2) rAAV comprising adenovirus genome and rep and cap genes flanked by AAV inverted terminal repeats.

ACTIVITY - Cytostatic; antisickling; antianemic; antiHIV.

MECHANISM OF ACTION - Gene therapy. No supporting data is given.

USE - The methods are useful for producing high titers of rAAV comprising therapeutic gene (claimed) which is useful in gene therapy for treating cancer and monogenic defects such as beta -thalassemia, sickle cell anemia, Fanconi anemia, chronic granulomatous disease, Gaucher disease, metachromatic leukodystrophy and cystic fibrosis, and Hodgkin's lymphoma, and human immunodeficiency virus (HIV) infection. rAAV produced by the methods is useful for diagnosis, disease monitoring and imaging (claimed).

ADVANTAGE - The method produces high titers of AAV (10⁷ T.U./ml) compared to titers (10⁴ T.U./ml) produced by conventional methods. The contamination of helper virus is also reduced.

8. Document ID: US 5981829 A

L2: Entry 8 of 14

File: DWPI

Nov 9, 1999

DERWENT-ACC-NO: 1999-633379

DERWENT-WEEK: 199954

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: New DELTANur77 transgenic mouse, useful as a model for defective apoptosis after T cell signaling

INVENTOR: CHENG, J; MOUNTZ, J D; ZHOU, T

PRIORITY-DATA: 1996US-0016914 (May 8, 1996), 1997US-0852173 (May 6, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 5981829 A	November 9, 1999	N/A	027	C12N005/00

INT-CL (IPC): C12N 5/00; C12N 15/00; C12N 15/09; C12N 15/63

ABSTRACTED-PUB-NO: US 5981829A

BASIC-ABSTRACT:

NOVELTY - A transgenic mouse whose genome comprises a truncated Nur77 (Delta Nur77) gene operably linked to a T-cell receptor (TCR) beta enhancer, is new.

DETAILED DESCRIPTION - The truncated Nur77 gene encodes a DNA binding protein of Nur77, where the transgene is expressed in the cells of the mouse such that the mouse exhibits defective T cell apoptosis mediated by T cell receptor signaling.

An INDEPENDENT CLAIM is also included for a double transgenic mouse made by the process of backcrossing the Delta Nur77 transgenic mouse with a Db/HY T cell receptor- alpha / beta transgenic mouse where expression of the transgenes from both parental strains results in one or more of a phenotype selected from:

(a) a five-fold increase in the number of thymocytes expressing self-reactive Db/HY TCR- alpha / beta relative to the Db/HY TCR- alpha / beta parental strain;

(b) a ten-fold increase in CD4+CD8+ thymocytes expressing the TCR- alpha / beta transgene relative to the Db/HY TCR- alpha / beta parental strain;

(c) an eight-fold increase in CD8+, Db/HY TCR- alpha / beta T cells in the lymph nodes relative male mice of the Db/HY TCR- alpha / beta parental strain; and

(d) increased activation and apoptosis of T cells associated with increased expression of Fas and Fas ligand in the lymph nodes relative to the Db/HY TCR- alpha / beta or Delta Nur77 parental strain.

USE - The double transgenic mouse is used:

(a) for detecting autoreactive lymph node T cells using antibodies directed against Fas and TCR and

(b) for screening for compounds that either up or down modulate the Fas/Fas ligand apoptosis system using the detection method of (a), where the results of (a) and (b) provide an in vivo model for analysis of autoreactive T cells undergoing tolerance through the Fas/Fas ligand apoptosis system (claimed).

The protein encoded by the Delta Nur77 protein has an inhibitory effect on the positive selection of thymocytes in female TCR transgenic mice. The Delta Nur77 transgenic mouse is useful as a model for defective apoptosis after T cell signaling and also for screening for reagents that induced apoptosis after T cell receptor signaling in the presence of the Delta Nur77 protein.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 9. Document ID: EP 1028626 A1, WO 9923879 A1, AU 9913896 A

L2: Entry 9 of 14

File: DWPI

Aug 23, 2000

DERWENT-ACC-NO: 1999-337610

DERWENT-WEEK: 200041

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Augmenting gene therapy, by administering tumor necrosis factor binding protein

INVENTOR: EDWARDS, C K; MOUNTZ, J D; ZHANG, H ; ZHOU, T

PRIORITY-DATA: 1997US-0064694 (November 7, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1028626 A1	August 23, 2000	E	000	A01N037/18
WO 9923879 A1	May 20, 1999	E	005	A01N037/18
AU 9913896 A	May 31, 1999	N/A	000	A01N037/18

INT-CL (IPC): A01N 37/18; C07K 1/00

ABSTRACTED-PUB-NO: WO 9923879A

BASIC-ABSTRACT:

NOVELTY - Increasing adenoviral gene expression in a tissue of an animal comprising administering a tumor necrosis factor binding protein (TNF-bp), is new.

ACTIVITY - Immunomodulatory.

MECHANISM OF ACTION - The TNF-bp results in a decrease in serum tumor necrosis factor- alpha (claimed).

USE - The method is useful for reducing an inflammatory response

USE - The method is useful for reducing an inflammatory response associated with adenoviral administration in a tissue of an animal (claimed), thus augmenting gene expression, especially useful during gene therapy.

ADVANTAGE - Prior art methods have lacked effective means for prolonging gene therapy expression. Mice infected with AdCMVlacZ virus were treated with the new TNF-bp, and there was decreased inflammatory disease and prolonged gene therapy for up to 30 days, compared to untreated mice.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------	-------

☐ 10. Document ID: AU 9875859 A, WO 9852615 A1

L2: Entry 10 of 14

File: DWPI

Dec 11, 1998

DERWENT-ACC-NO: 1999-045282

DERWENT-WEEK: 199917

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Promotion of immunotolerance in a host to a gene therapy vector - comprises use of a vector expressing transgene, antigen and ligand inducing apoptosis in T-cell raised against antigen, used in gene therapy

INVENTOR: CURIEL, D T; MOUNTZ, J D; ZHANG, H

PRIORITY-DATA: 1997US-0047426 (May 22, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 9875859 A	December 11, 1998	N/A	000	A61K048/00
WO 9852615 A1	November 26, 1998	E	093	A61K048/00

INT-CL (IPC): A61K 48/00; C12N 15/63

ABSTRACTED-PUB-NO: WO 9852615A

BASIC-ABSTRACT:

A novel method for promoting immunotolerance in a host to a gene therapy vector comprises transfecting a host cell with the vector such that the vector expresses a transgene, an antigen and a ligand, and expression of the ligand induces apoptosis in a T-cell raised against the antigen in the host. The method optionally further comprises exposing host to a second vector following therapeutic gene expression, second vector expressing same antigen and a second ligand which also induces apoptosis in the T-cell on expression. Also claimed are: (1) creating an immune privileged site in a tissue of an organism, by infecting cells of the tissue with a vector as above, such that expression of the ligand in the tissue induces apoptosis of T-cells raised against the antigen to confer specific immunity to the infected cells, and (2) gene therapy viral vectors: (i) comprising a transgene, an apoptosis ligand gene, a gene expression control means for directing product synthesis of transgene and ligand gene in the host and optionally an enhancer, and (ii) as in (i) but in which ligand gene is a functional equivalent of a Fas ligand gene and also

comprising a viral vector gene expressed as an antigen on infected host cell.

USE - The methods and vectors are useful in gene therapy (claimed) (especially to correct a gene defect of a target tissue cell e.g. an erythrocyte, bone marrow cell (claimed) or to suppress immune responses in autoimmune diseases. Method (1) can be used to create an immune suppressed zone of tissue within the organism, useful for organ transplantation. Host cells may be transfected with the vector either in vitro or in vivo (e.g. by an intra-nasal or intravenous pathway) (claimed), and it is possible to transfect specialised antigen presenting cells (APCs) with vectors expressing the Fas ligand, to obtain presentation of viral antigens and Fas ligand on the APCs. The introduction of the APCs into an organism can then induce apoptosis of T-cells expressing Fas, eliminating those reacting with the antigens from the vector.

ADVANTAGE - Previous use of gene therapy viral vectors has been limited by T-cell mediated immune responses, which can lead to rapid virus clearance and loss of transgene expression; by including in the vector a ligand inducing apoptosis of T-cells raised against the antigen expressed by the vector, the method can suppress the immune response to the antigen.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw. Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------	-------

☐ 11. Document ID: AU 9876871 A, WO 9851340 A1

L2: Entry 11 of 14

File: DWPI

Dec 8, 1998

DERWENT-ACC-NO: 1999-034770
DERWENT-WEEK: 199916
COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Induction of systemic tolerance to an antigen - by administering antigen presenting cells which express Fas ligand and antigen acts by affecting apoptosis

INVENTOR: MOUNTZ, J D; ZHOU, T

PRIORITY-DATA: 1997US-0046560 (May 15, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 9876871 A	December 8, 1998	N/A	000	A61K039/12
WO 9851340 A1	November 19, 1998	E	077	A61K039/12

INT-CL (IPC): A61K 39/12; A61K 39/235; A61K 48/00; C07K 14/005; C07K 14/435

ABSTRACTED-PUB-NO: WO 9851340A

BASIC-ABSTRACT:

A method is claimed for inducing tolerance to an antigen in an individual by adding antigen presenting cells (APCs) which express Fas ligand and the antigen. The APCs induce apoptosis of Fas-positive cells directed to the antigen. Also claimed is the step of delivering to the APCs a gene to inhibit apoptosis. Further claimed is a method of increasing expression of a transgene in an individual by administering APCs expressing Fas ligand and an antigen to the protein product of the transgene and then delivering a viral vector encoding a transgene where the APCs induce apoptosis of Fas-positive cells. Also claimed is a method of creating immune-privileged sites in an individual to decrease rejection of a graft. The APCs are extracted from donor organ tissue and Fas ligand is introduced to produce Fas ligand-expressing APCs expressing an antigen specific to the graft. The cells are then introduced to the graft prior to and during the grafting procedure.

USE - T-cell tolerance to a virus in an individual receiving gene therapy is induced which involves: (i) transfecting Fas ligand expressing APCs with the virus; (ii) introducing the transfected APCs into the individual; (iii) treating the individual with the virus for the purpose of gene therapy where the APCs expressing the Fas ligand induce T-cell tolerance to the virus; (iv) delivering a gene to the antigen presenting cells to inhibit apoptosis. The method decreases rejection of a graft in an individual by perfusing donor organ tissue with Fas ligand and then introducing the donor organ tissue to the individual.

ADVANTAGE - This invention uses Fas ligand technology which prior arts do not employ. The importance of Fas-mediated apoptosis in the maintenance of T-cell tolerance and prevention of autoimmune disease has previously been demonstrated (Watanabe- Fukunaga et al Nature 356, 314-317, 1992 and Suda et al Cell 75 1169-1178, 1993).

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWAC	Drawn Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------	-------

12. Document ID: US 5888764 A, WO 9622370 A1, AU 9650201 A

L2: Entry 12 of 14

File: DWPI

Mar 30, 1999

DERWENT-ACC-NO: 1996-354527
DERWENT-WEEK: 199920
COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Human Fas gene promoter region - used for heterologous protein expression and for developing products for treating Fas-mediated apoptosis disorders

INVENTOR: CHENG, J; KOOPMAN, W J ; LIU, C ; MOUNTZ, J D ; ZHOU, T

PRIORITY-DATA: 1995US-0377522 (January 20, 1995)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 5888764 A	March 30, 1999	N/A	000	C12N001/21
WO 9622370 A1	July 25, 1996	E	123	C12N015/12
AU 9650201 A	August 7, 1996	N/A	000	C12N015/12

INT-CL (IPC): A01K 67/027; C07K 14/715; C12N 1/21; C12N 5/10; C12N 15/11; C12N 15/12; C12N 15/67; C12N 15/86; C12P 21/00 ; C12Q 1/68

ABSTRACTED-PUB-NO: US 5888764A

BASIC-ABSTRACT:

A novel DNA segment (I) has an isolated sequence region defined as the Fas gene promoter region (FPR). Also claimed are: (1) a DNA molecule (II) comprising a DNA segment having the Fas control elements as in (I) operably linked to a structural gene not ordinarily under the transcriptional control (TC) of the control elements; (2) a nucleic acid segment (III) comprising at least a 10 nucleotide contiguous stretch corresponding to a contiguous stretch of a 1608 bp sequence given in the specification; and (3) a recombinant host cell, pref. eukaryotic, comprising (I).

USE - The prods. and methods can be used in diagnostic and screening assays and for protein expression. They can be used to develop prods. for treating disorders associated with Fas mediated apoptosis such as autoimmune diseases and malignancies. The FPR can also be used for the expression of heterologous structural genes for e.g. TGFalpha, TGFbeta, EGF, FGF, TNFalpha, p53, c-myc, c-fos, G-CSF or GM-CSF (claimed).

ABSTRACTED-PUB-NO:

WO 9622370A EQUIVALENT-ABSTRACTS:

A novel DNA segment (I) has an isolated sequence region defined as the Fas gene promoter region (FPR). Also claimed are: (1) a DNA molecule (II) comprising a DNA segment having the Fas control elements as in (I) operably linked to a structural gene not ordinarily under the transcriptional control (TC) of the control elements; (2) a nucleic acid segment (III) comprising at least a 10 nucleotide contiguous stretch corresponding to a contiguous stretch

of a 1608 bp sequence given in the specification; and (3) a recombinant host cell, pref. eukaryotic, comprising (I).

USE - The prods. and methods can be used in diagnostic and screening assays and for protein expression. They can be used to develop prods. for treating disorders associated with Fas mediated apoptosis such as autoimmune diseases and malignancies. The FPR can also be used for the expression of heterologous structural genes for e.g. TGF alpha , TGF beta , EGF, FGF, TNF alpha , p53, c-myc, c-fos, G-CSF or GM-CSF (claimed).

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Draw. Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	------------	-------

☐ 13. Document ID: MX 9704780 A1, WO 9620206 A1, AU 9646917 A, AU 705281 B

L2: Entry 13 of 14

File: DWPI

May 1, 1998

DERWENT-ACC-NO: 1996-321796

DERWENT-WEEK: 200007

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Natural, soluble form of Fas antigen secreted by human cells is result of alternative mRNA processing - used to diagnose Fas-associated disease, e.g. systemic lupus erythematosus

INVENTOR: CHENG, J; LIU, C ; MOUNTZ, J D; ZHOU, T

PRIORITY-DATA: 1994US-0371263 (December 23, 1994)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
MX 9704780 A1	May 1, 1998	N/A	000	C07H021/04
WO 9620206 A1	July 4, 1996	E	152	C07H021/04
AU 9646917 A	July 19, 1996	N/A	000	C07H021/04
AU 705281 B	May 20, 1999	N/A	000	C07H021/04

INT-CL (IPC): A61K 38/18; A61K 38/19; C07H 21/04; C07K 14/475; C07K 14/52; C12Q 1/68; G01N 33/53

ABSTRACTED-PUB-NO: WO 9620206A

BASIC-ABSTRACT:

Compsn. comprises an isolated Fas antigen (Ag) contg. part of the Fas Ag intracellular and extracellular regions, and where at least a part of the Fas Ag transmembrane region is deleted. Also claimed are: (1) a polypeptide comprising a sequence region that consists of at least a 10 residue long contiguous sequence as set forth by the contiguous amino acid sequence from Lys at position 164 to Glu at position 173 of a 314 amino acid sequence (given in the specification); (2) an antibody (Ab) that binds to the Fas Ag epitope as above; (3) a nucleic acid segment (I) comprising a coding region for a soluble Fas Ag as above; and (4) a recombinant host cell incorporating (I).

USE - (I) is useful for the prodsn. of soluble Fas Ag polypeptide (claimed). It can also be used as a specific probe to screen cDNA libraries to identify and clone the Fas ligand. The Ab is useful to detect soluble Fas Ag polypeptide in a sample (claimed), and may also

detect soluble Fas Ag polypeptide in a sample (claimed), and may also be administered to animals as part of a treatment regimen for autoimmune disease. The amt. of soluble Fas Ag can be determined to diagnose a Fas-associated disease, partic. systemic lupus erythematosus or angioimmunoblastic lymphadenopathy.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw. Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	------------	-------

☐ 14. Document ID: WO 9408454 A1

L2: Entry 14 of 14

File: DWPI

Apr 28, 1994

DERWENT-ACC-NO: 1994-150823

DERWENT-WEEK: 199418

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: New nucleic acid encoding Fas protein with ETn gene insert - is used for detecting apoptosis defective T-cells implicated in development of auto-immune disease, and screening potential therapeutic agents

INVENTOR: MOUNTZ, J D

PRIORITY-DATA: 1993US-0097826 (July 23, 1993), 1992US-0961164 (October 14, 1992)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9408454 A1	April 28, 1994	E	076	A01N001/00

INT-CL (IPC): A01N 1/00; C07H 5/00; C07K 7/00; C07K 13/00; C12Q 1/00

ABSTRACTED-PUB-NO: WO 9408454A

BASIC-ABSTRACT:

Purified nucleic acid segment (A), free from genomic DNA, includes a sequence (I) encoding a Fas cell surface protein and an ETn gene sequence (II).

Also new are (1) apoptosis-defective mutant protein (72 amino acids, reproduced in the specification); (2) method for detecting apoptosis-defective T-cells; (3) method for identifying substances able to promote normal apoptosis in apoptosis-defective cells and (4) the identified substances (III).

Pref. (A) encodes an apoptosis-defective Fas protein and has (II) inserted within the Fas coding sequence (esp. at position 232 of the Fas gene. The specification includes sequences of (II), 168 bp, and of a fragment (216 bp) encoding the mutant Fas protein.

USE - The method is based on the discovery that insertion of the ETn (retroviral transposon) sequence into the fas apoptosis gene induces autoimmune disease (the insert renders the fas gene dysfunctional). Detection of apoptosis-defective T-cells indicates risk of developing systemic autoimmune disease and (III) can be used to treat systemic autoimmune or lymphoproliferative diseases.

Generate Collection

Term	Documents
MOUNTZ-JOHN-D.DWPI,EPAB,JPAB,USPT,PGPB.	5
MOUNTZ-J-D.DWPI,EPAB,JPAB,USPT,PGPB.	8
ZHOU-TONG.DWPI,EPAB,JPAB,USPT,PGPB.	5
(MOUNTZ-JOHN-D ZHOU-TONG MOUNTZ-J-D)! DWPI,EPAB,JPAB,PGPB,USPT.	14

Display

☐

Documents, starting with Document:

Display Format:

Change Format